matt

T2 · manager / operator

Matt has been at Accel for 15 years, focusing on infrastructure and neoclouds. He led the $150M PIPE into Nebius 16 months ago (up 13x) and drives the firm's thesis on AI infrastructure scaling, token economics, and late-stage private market dynamics.

18 calls·15 names·78% bull·last heard 7 days ago·Sequoia Capital+3
track record

no scored calls yet — needs a stated position or a categorical verdict, with a matured window vs SPY

top calls

highest conviction · one per company
1sthigh conviction
$CHAI-DISCOVERYChai Discoveryposition

Chai 2 achieves 15% antibody binding rate vs 0.1% prior art

Chai Discovery's Chai 2 model reaches 15% success rate in de novo antibody design versus 0.1% state-of-the-art, enabling zero-shot molecule generation with sufficient hits for statistical property optimization and hill-climbing.

2ndhigh conviction
$BWXTBWX Technologiesposition

BWXT primary Navy nuclear supplier positioned for coming commercial nuclear cycle

BWXT supplies nuclear components for the US Navy and has significant dollar content in AP1000 reactors, positioning it to benefit from the necessary large-scale nuclear buildout in the 2030s.

3rdhigh conviction
$XPLRXPLR Infrastructureposition

XPLR solar assets set for windfall as gas prices drive power margins higher

Utility-scale solar assets with PPAs marked to market will capture widening margins as gas-fired generation sets higher power prices, requiring no incremental capex.

18 total
$CHAI-DISCOVERY
Chai Discovery
HIGHmatt·Sequoia Capital·7 days ago· position
Chai 2 achieves 15% antibody binding rate vs 0.1% prior art
Chai Discovery's Chai 2 model reaches 15% success rate in de novo antibody design versus 0.1% state-of-the-art, enabling zero-shot molecule generation with sufficient hits for statistical property optimization and hill-climbing.
"Yeah, if we look at the the quality of the molecules that's coming out, if it goes back to, you know, one of the thesis when we started the company that uh we really wanted to foc…"
15:22
$CHAI-DISCOVERY
Chai Discovery
HIGHmatt·Sequoia Capital·7 days ago· position
Deployment flywheel spinning: pharma partners using models on real disease programs
Chai Discovery's models are now deployed with pharma partners on real programs targeting devastating diseases; zero-shot molecules advancing to clinic within a year, with potential for dozens to hundreds of Chai-designed molecules entering patients in coming years.
"I think for me it's uh just the deployments uh that are happening. So, we've announced a couple of these these partnerships and I'm really excited uh just to hear about the result…"
44:29
$CHAI-DISCOVERY
Chai Discovery
HIGHmatt·Sequoia Capital·7 days ago· position
Bitter lesson drives Chai: scaling laws beat hand-crafted modules
Chai Discovery follows the 'bitter lesson' — scaling compute, data, and simple architectures outperforms complex hand-engineered modules; identifying scaling laws lets models automatically learn hidden biological features like glycosylation sites without explicit modules.
"Yeah. So, one thing that I really like about Chai is like we're we're a very bitter lesson and impilled company. So, like we really believe in like scaling data, scaling models, s…"
18:45
$CHAI-DISCOVERY
Chai Discovery
HIGHmatt·Sequoia Capital·7 days ago· position
Platform model chosen over full-stack: pharma partnerships create rigor flywheel
Chai Discovery chose an infrastructure/platform model partnering with pharma giants (Eli Lilly, Novartis, Organon, Pfizer) over full-stack drug development; partnerships force model rigor, create revenue flywheel to fund better models, and avoid diverting resources to clinical trials.
"Yeah, first of all, I think both of these paths are are great and uh uh they can they can create tremendous value. We've always been really excited about building infrastructure f…"
28:38
$SERVA
Serva
HIGHmatt·Scaling Europe·2 months ago· position
Serva designs personalized oncology drugs from blood droplet in hours, already dosing patients
Serva uses AI models trained on proprietary data to design personalized oncology drugs under single-patient INDs, moving from blood droplet to treatment in hours, already dosing patients including the GitLab founder's cancer vaccine, with £8M pre-seed raised.
"We implement models that we build and train on data that we generate ourselves and use this to design drugs for patients under single patient INDs which means that we're already d…"
35:23
$BWXT
···
BWX Technologies
HIGHmatt·Invest Like The Best·21 days ago· position
BWXT primary Navy nuclear supplier positioned for coming commercial nuclear cycle
BWXT supplies nuclear components for the US Navy and has significant dollar content in AP1000 reactors, positioning it to benefit from the necessary large-scale nuclear buildout in the 2030s.
"BWXT which is a super interesting company with um they're the primary supplier of nuclear for the US Navy. they they significantly benefit from you know the coming nuclear cycle a…"
33:23
$CAT
···
Caterpillar
HIGHmatt·Invest Like The Best·21 days ago
Caterpillar doubling Solar Turbine capacity at exact wrong time for gas availability
Caterpillar is expanding distributed gas turbine capacity through 2029 just as structural gas scarcity makes gas-fired generation uneconomic, risking stranded assets and order slowdowns.
"Caterpillar. Um, Caterpillar is I think they're doubling their uh, solar turbine capacity between now and the end of 29, which I would judge is just at the exact wrong time when p…"
36:00
$BE
···
Bloom Energy
HIGHmatt·Invest Like The Best·21 days ago
Bloom Energy fuel cells cannot secure gas supply at scale in structural deficit
Bloom's fuel cells require 150 MMcf/day per GW and planned 2-5 GW/year manufacturing capacity cannot be supported by available gas when competing with all other gas-fired generation in a tight market.
"Bloom energy have been topical recently because of other other things that folks are talking about the rarest they use in their manufacturer for instance. for us. Um, we don't thi…"
36:17
$XPLR
···
XPLR Infrastructure
HIGHmatt·Invest Like The Best·21 days ago· position
XPLR solar assets set for windfall as gas prices drive power margins higher
Utility-scale solar assets with PPAs marked to market will capture widening margins as gas-fired generation sets higher power prices, requiring no incremental capex.
"XPLR tickers X IFR formerly Nextera Yield Co which is an interesting interesting set of assets they have a a windfall coming in the latter part of the decade in early 2030s Cedus…"
27:25
$EXE
···
Expand Energy
HIGHmatt·Invest Like The Best·21 days ago· position
Expand Energy top natural gas winner with 70% of core Haynesville inventory
Expand controls 70% of remaining core Haynesville wells with known productive parameters, trading at 4x EBITDA on a complacent forward curve while structural gas deficit looms in 2028-2030.
"Expand Energy is probably at the top of that list. They probably control 70% of remaining core Hanesville wells of the very closely known parameters of rock where we know it to be…"
25:22